Trump Administration’s $500 Million Flu Vaccine Grant Raises Eyebrows in Scientific Community

#VaccineFunding #UniversalFluVaccine #TrumpAdministration #NIH #PandemicPreparedness

A Controversial Investment in Outdated Technology

The Trump administration’s decision to allocate $500 million toward a flu vaccine that uses technology largely abandoned decades ago has puzzled vaccine researchers and public health experts. While the goal is to create a universal influenza vaccine, the choice to back an early-stage project—led by two Trump-appointed scientists at the National Institutes of Health (NIH)—has sparked criticism for its scientific and ethical implications.

Questions Over Process and Transparency

The funds were redirected from a pandemic preparedness program to the so-called “Generation Gold Standard” initiative, developed by Dr. Jeffery Taubenberger and Dr. Matthew Memoli. Critics argue that the project, still in its early development stages and based on outdated whole-virus vaccine methods, did not go through a rigorous or competitive review process, unlike Operation Warp Speed, which involved extensive vetting of candidates during the COVID-19 crisis.

Vaccine expert Dr. William Schaffner likened the strategy to betting everything on a single horse, a rare move in the scientific world where diversified research is the norm.

Concerns About the Technology and Its Efficacy

Taubenberger and Memoli’s vaccine revives whole-virus inactivation techniques that were standard in the mid-20th century but were phased out due to side effects such as fevers and seizures. Their vaccine is created using beta-propiolactone, a chemical used since the 1950s to inactivate viruses. Although early trials involving 45 people showed no major side effects, the vaccine remains far behind other universal flu vaccine candidates in development.

According to Dr. Rick Bright, former head of HHS’ Biomedical Advanced Research and Development Authority (BARDA), the approach is outdated and far less promising than mRNA-based or AI-assisted strategies being pursued today.

Political Motives and Personnel Moves

Both Taubenberger and Memoli were recently appointed to high-level NIH positions by the Trump administration. Memoli briefly served as interim NIH director before being named principal deputy under current director Jay Bhattacharya. The appointments, paired with the funding decision, have raised concerns about potential conflicts of interest and political influence.

Health and Human Services (HHS) has framed the initiative as transparent and free from commercial bias. However, the lack of published human trial data and the bypassing of existing vaccine development networks have added to the skepticism. HHS has yet to offer detailed evidence supporting the decision beyond a brief press statement.

Fallout for Other Research Programs

The funding for this initiative appears to come from Project NextGen, originally focused on advanced research into COVID-19 and other emerging infectious diseases. Experts warn that the diversion of funds away from newer vaccine technologies and pandemic threats could weaken preparedness.

Dr. Paul Friedrichs, a former official in pandemic response, criticized the decision as unprecedented and risky. He emphasized that the move could undermine efforts to prepare for future COVID variants, especially if immunity levels decline.

Ongoing Uncertainty for Researchers

While some scientists, like Ted Ross at the Cleveland Clinic, welcomed investment in respiratory vaccines, many remain frustrated. Ross, whose team is developing AI-designed universal flu vaccines under the NIH-funded consortium, now faces uncertainty regarding future funding as NIH grants and positions are slashed.

Memoli oversaw the beginning of major NIH budget cuts that have already eliminated over 800 grants and left more than 1,200 employees without jobs. As the administration pivots sharply in its funding strategy, many promising programs hang in the balance.

Ross summed up the concern shared by many: “I don’t think this is the only approach. Others are further along, and we don’t yet know which will succeed. But now, we may not get the chance to find out.”